Elaborate biologic approval process delays care of patients with moderate-to-severe asthma

BACKGROUND: mAbs (biologics) are indicated in patients with poorly controlled moderate-to-severe asthma. The process of prior authorization and administration of a biologic requires exceptional commitment from clinical teams. OBJECTIVE: Our aim was to evaluate the process of approval and administrat...

Descripción completa

Detalles Bibliográficos
Autores principales: Sehanobish, Esha, Ye, Kenny, Imam, Kamran, Sariahmed, Karim, Kurian, Joshua, Patel, Jalpa, Belletti, Daniel, Chung, Yen, Jariwala, Sunit, White, Andrew, Jerschow, Elina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509902/
https://www.ncbi.nlm.nih.gov/pubmed/37780792
http://dx.doi.org/10.1016/j.jacig.2022.10.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509902/
https://www.ncbi.nlm.nih.gov/pubmed/37780792
http://dx.doi.org/10.1016/j.jacig.2022.10.007

Ejemplares similares